Smith C A, Ng C Y, Heslop H E, Holladay M S, Richardson S, Turner E V, Loftin S K, Li C, Brenner M K, Rooney C M
Department of Virology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
J Hematother. 1995 Apr;4(2):73-9. doi: 10.1089/scd.1.1995.4.73.
EBV-induced lymphoproliferative disease (EBV-LPD) is a disorder most commonly associated with the immunocompromise that follows allogeneic organ transplantation. In patients receiving T cell-depleted bone marrow from HLA-mismatched or HLA-matched unrelated donors, the incidence of EBV-LPD is particularly high, ranging from 5 to 30%. Administration of EBV-specific cytotoxic T lymphocytes may be one means of preventing and treating this disease. We now describe a method that allows the routine and timely preparation of large numbers of such cells to allow their safe administration to bone marrow transplant recipients. We also describe how these cells may be genetically marked before infusion, to determine their fate and disposition in vivo.
爱泼斯坦-巴尔病毒（EBV）诱导的淋巴增殖性疾病（EBV-LPD）是一种最常与同种异体器官移植后免疫功能低下相关的疾病。在接受来自HLA不匹配或HLA匹配的无关供体的T细胞去除骨髓的患者中，EBV-LPD的发病率特别高，范围从5%到30%。给予EBV特异性细胞毒性T淋巴细胞可能是预防和治疗这种疾病的一种方法。我们现在描述一种方法，该方法能够常规且及时地制备大量此类细胞，以便将其安全地给予骨髓移植受者。我们还描述了在输注前如何对这些细胞进行基因标记，以确定它们在体内的命运和分布情况。
